Bristol Medicaid subpoena
Executive Summary
Bristol-Myers Squibb "best price" reporting requirements under Medicaid are the subject of a subpoena from Massachusetts U.S. Attorney's Office, company says in Securities & Exchange Commission filing Aug. 8. Bristol recently commenced an "internal review" to determine whether Medicaid rebates and pricing practices have been appropriate (1"The Pink Sheet" July 28, 2003, p. 33). Bristol met with Boston U.S. Attorney's Office to "discuss the review and its plan for sharing the results of the review," filing says. The company "subsequently received a subpoena...relating to the subject matter of the review"...
You may also be interested in...
Bristol Earnings Feature Downside Disclosures But Still Rely On Restructuring
Bristol is signaling another round of restructuring for the end of 2003 as it prepares for the next wave of patent expirations
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.